In this issue of Blood, Pluskota and colleagues reveal a new prothrombotic pathway initiated by neutrophil-derived microparticles through the interaction of the leukocyte integrin Mac-1 (␣ M ␤ 2 ) on microparticles with its counterreceptor on platelets, GPIb␣, the major ligand-binding subunit of the GPIb-IX-V complex (see figure). These findings have broad implications for the pathogenesis, monitoring, and/or future therapy of inflammatory/thrombotic disease.
A ll inflammatory/thrombotic vascular cells (leukocytes, platelets, endothelial cells) generate microparticles, small membrane-bound vesicles budded off from the parent cell that generally reflect that cell's surface-receptor profile. Microparticles are not just by-products of cellular activation or apoptosis, but are functional and modulate the activity of other cells.
They also represent potentially selective biomarkers of diseases involving cellular perturbation. 1 One important role for leukocyte-derived microparticles is to deliver clot-promoting tissue factor rapidly to a developing thrombus. 2 In this case, Pselectin glycoprotein ligand-1 (PSGL-1) on the microparticle targets activated platelets by binding platelet P-selectin. Activated platelets are also strongly procoagulant due to increased exposure of phosphatidyl serine, the expression of coagulation factorbinding receptors, the secretion of polyphosphates, and through glycoprotein (GP) Ib␣, which acts as a molecular scaffold localizing coagulation factors such as highmolecular-weight kininogen, factors XI and XII, and thrombin. 3 Interestingly, the present findings indicate that leukocytederived microparticles play another potential role in thrombus development by acting as a novel platelet agonist targeting GPIb␣. This provides a potential explanation of how chronic inflammation can perpetuate a prothrombotic phenotype.
Pluskota and colleagues show that microparticles derived from activated neutrophils express functional Mac-1 and act as platelet agonists by virtue of Mac-1 binding platelet GPIb␣. GPIb␣ is a constitutively expressed platelet-adhesion receptor that initiates thrombus formation at arterial shear rates by binding von Willebrand factor (VWF) or other ligands. 3, 4 Engagement of GPIb␣ by Mac-1-bearing microparticles leads to phosphorylation of the signaling protein Akt, which is an intermediary in GPIb␣-dependent signaling downstream of phosphatidyl inositol (PI) 3-kinase activation, and upstream of surface expression of Pselectin and activation of ␣ IIb ␤ 3 (which binds fibrinogen and VWF and mediates
The expression on neutrophil-derived microparticles of the integrin Mac-1 (␣M␤2) in an active conformation provides a new mechanism for leukocyte-platelet crosstalk. In contrast to microparticles from resting neutrophils, microparticles from PAF-or PMA-stimulated neutrophils express Mac-1 where the insert or 'I' domain on the ␣M subunit is in a high-affinity ligand-binding form. This can bind platelet GPIb␣ (the major ligand-binding subunit of the GPIb-IX-V complex), leading to platelet activation and P-selectin expression, which reinforces association via microparticle PSGL-1.
platelet aggregation). P-selectin expressed on the activated platelets can bind PSGL-1, strengthening the association between the activated neutrophil microparticle and the platelets. It has been previously established that GPIb␣ directly binds activated leukocyte Mac-1, 5 as well as P-selectin expressed on activated platelets/endothelial cells, 3, 6 enabling GPIb␣-mediated plateletleukocyte-endothelial cell crosstalk; for example, platelets strongly promote vascular adhesion of leukocytes in atherogenesis. 7 Binding of P-selectin on activated platelets or platelet microparticles to leukocyte PSGL-1 initiates signals activating Mac-1, thereby enabling integrin-dependent adhesion to endothelial cells via intercellular adhesion molecule-1 (ICAM-1), or to mural platelets via GPIb␣ (see figure) .
One of the key findings from this study is that, whereas microparticles derived from unstimulated neutrophils contain relatively low levels of Mac-1 in an inactive state, microparticles derived from PMA-or PAFactivated neutrophils contain approximately10-fold enrichment of Mac-1 present in an activated state, where the insert or "I" domain in the ␣ M subunit is in a highaffinity ligand-binding form. This was established by binding of conformationdependent antibodies or the Mac-1 ligand, fibrinogen. These relative levels of inactive/ active Mac-1 in microparticles are thought to depend on lipid raft constituency before or after stimulation. This is because microparticles are likely derived from these membrane domains, and activated Mac-1 is enriched in rafts following neutrophil stimulation. There is thus a built-in differential adhesive capacity of microparticles from unstimulated versus activated neutrophils to facilitate interaction with either activated platelets (via PSGL-1/P-selectin) or resting platelets (via active Mac-1/GPIb␣), respectively. This implies that microparticledependent platelet activation occurs under conditions where neutrophils are also activated; conversely, microparticles generated from quiescent neutrophils (expressing inactive Mac-1) would be limited to interacting only with activated platelets (expressing surface P-selectin).
What, then, is the relevance of these new findings to inflammation and thrombosis, and is there potential diagnostic value in measuring the proportion of total neutrophil-derived microparticles expressing activated Mac-1 as a biomarker for pathological inflammation/ thrombosis? This remains to be determined, but the new discoveries by Pluskota and colleagues demonstrate a clear prothrombotic functional pathway for this microparticle subtype. ---------------------------------------------------------------------------------------------------------------- 
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Leukemia takes center (late) stage
Utpal P. Davé VANDERBILT UNIVERSITY MEDICAL CENTER
In this issue of Blood, Newrzela and colleagues present experiments that show how mature T lymphocytes are resistant to transformation by retrovirally transduced T-cell oncogenes. R etroviral transduction of hematopoietic stem cells and progenitors is used to evaluate the function of putative oncogenes and is a common way to deliver therapeutic transgenes. Constitutive expression of an oncogene activated by nearby insertion of a retroviral promoter can result in a phenotype similar to sporadically occurring gain-of-function mutations in the same oncogene. Likewise, retroviral integration near an oncogene can deregulate its expression, mimicking chromosomal rearrangements that exert the same effect in sporadically occurring leukemias. In such experiments testing oncogene function, the preferred target cell for retroviral transduction is the hematopoietic stem cell (HSC) because it gives long-term reconstitution of hematopoiesis in lethally irradiated hosts and is capable of self-renewal, an important hallmark of cancer. Lymphocytes are unique among hematopoietic lineages in that they also can self-renew. 1 Then, does it follow that mature T cells are as susceptible to oncogenic transformation as HSCs?
Newrzela et al address this question through retroviral delivery of 3 potent oncogenes, LIM domain Only-2 (LMO2), T-cell Leukemia-1 (TCL1), and ⌬-TrkA. LMO2 is translocated to T-cell receptor loci in 5% to10% of T-cell acute lymphoblastic leukemias (T-ALL). 2 Typically, these leukemias arise from immature T cells in the thymus. LMO2 was also deregulated in 4 cases of gene therapy induced leukemias where the gamma-retroviral vector insertionally activated the oncogene. TCL1 deregulation was also originally discovered through analysis of a recurrent chromosomal translocation in a mature T-cell leukemia. 3 ⌬-TrkA was cloned from a human acute myeloid leukemia. 4 This truncated and constitutively active form of TrkA gives rise to myeloid and immature T-cell leukemias when retrovirally transduced into HSCs. 5 In the experiments detailed in the paper by Newrzela et al, these 3 oncogenes were retrovirally transduced in HSCs and mature T cells, and the cells were subsequently transplanted into irradiated hosts. The researchers attained high-level expression of the transferred genes in both target cell populations, and transduced cells could be followed by unique cell surface markers in RAGdeficient recipient mice. 
